If you have been reading about gastric juice protein and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
After the inauguration of Barack Obama, Bush and his family flew from Andrews Air Force Base to a homecoming celebration in Midland, Texas, and then returned to their ranch in Crawford, Texas. They bought a home in the Preston Hollow neighborhood of Dallas where they live. Bush made regular appearances at various events throughout the Dallas–Fort Worth area, including the opening coin toss at the Dallas Cowboys' first game in the new Cowboys Stadium in Arlington and an April 2009 Texas Rangers game, where he thanked the people of Dallas for helping him settle in, which was met with a standing ovation. He also attended every home playoff game during the Rangers' 2010 season and, accompanied by his father, threw out the ceremonial first pitch at the Rangers Ballpark in Arlington for Game 4 of the 2010 World Series on October 31. He also threw the first pitch in Game 1 of the 2023 World Series. On August 6, 2013, Bush was successfully treated for a coronary artery blockage with a stent. The blockage had been found during an annual medical examination. In reaction to the 2016 shooting of Dallas police officers, Bush said: "Laura and I are heartbroken by the heinous acts of violence in our city last night. Murdering the innocent is always evil, never more so than when the lives taken belong to those who protect our families and communities."
A milestone in that process was the work of Linus Pauling in 1949, which for the first time linked the specific genetic mutation in patients with sickle cell disease to a demonstrated change in an individual protein, the hemoglobin in the erythrocytes of heterozygous or homozygous individuals.
== External links == mTOR+protein at the U.S. National Library of Medicine Medical Subject Headings (MeSH) "mTOR Signaling Pathway in Pathway Interaction Database". National Cancer Institute. Archived from the original on 2013-03-18. Retrieved 2015-10-18. Overview of all the structural information available in the PDB for UniProt: P42345 (Serine/threonine-protein kinase mTOR) at the PDBe-KB.
==== Don Cossacks in World War II ==== In April 1936, the earlier ban on Cossacks serving in the Red Army was lifted. Later in 1936, two existing Red Army cavalry divisions were re-designated as Don Cossacks. In 1939, a number of these regiments were issued with traditional Cossack uniforms, in ceremonial and field service versions. The dress of the Don Cossack units included dark-blue breeches with broad red stripes which had distinguished them prior to the Revolution. The Don Cossack Cavalry Corps saw extensive active service until 1943, after which its role diminished, as did that of the other remaining horse-mounted units in the Red Army. However Don Cossack cavalry was still in existence in 1945 and participated in the Victory Parade in Moscow. During World War II, the Don Cossacks mustered the largest single concentration of Cossacks within the German Army, the XVth SS Cossack Cavalry Corps, a great part of them former Soviet citizens. The XVth SS Cossack Cavalry Corps included the 1st Cossack Division and the 2nd Cossack Division. The majority of the Cossacks remained loyal to the Red Army. In the earliest battles, particularly the encirclement of Belostok, Cossack units such as the 94th Beloglisnky, 152nd Rostovsky and 48th Belorechensky regiments fought to their death. In the opening phase of the war, during the German advance towards Moscow, Cossacks were extensively used for raids behind enemy lines.
== Function == Cytosolic and membrane-bound forms of glutathione S-transferase are encoded by two distinct supergene families. These enzymes are involved in cellular defense against toxic, carcinogenic, and pharmacologically active electrophilic compounds. At present, eight distinct classes of the soluble cytoplasmic mammalian glutathione S-transferases have been identified: alpha, kappa, mu, omega, pi, sigma, theta and zeta. This gene encodes a glutathione S-transferase belonging to the alpha class. The alpha class genes, which are located in a cluster on chromosome 6, are highly related and encode enzymes with glutathione peroxidase activity that function in the detoxification of lipid peroxidation products. GSTA4 shows very high activity with reactive carbonyl compounds such as alk-2-enals. GSTA4 is highly effective in catalyzing the conjugate addition of reduced glutathione to 4-hydroxynonenal, an important product of peroxidative degradation of arachidonic acid and a commonly used biomarker for oxidative damage in tissue.
Sources: en.wikipedia.org
== External links == Dagli AI, Mathews J, Williams CA (May 2025). "Angelman Syndrome". In Adam MP, Bick S, Mirzaa GM, et al. (eds.). GeneReviews® [Internet]. University of Washington, Seattle. PMID 20301323. NBK1144. OMIM entries on Angelman syndrome UniProt entry for ubiquitin "7.340 Ubiquitination: The Proteasome and Human Disease". MIT OpenCourseWare. 2004. Notes from MIT course. Ubiquitin at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
A 2014 study suggests that bromine (in the form of bromide ion) is a necessary cofactor in the biosynthesis of collagen IV, making the element essential to basement membrane architecture and tissue development in animals. Nevertheless, no clear deprivation symptoms or syndromes have been documented in mammals. In other biological functions, bromine may be non-essential but still beneficial when it takes the place of chlorine. For example, in the presence of hydrogen peroxide, H2O2, formed by the eosinophil, and either chloride, iodide, thiocyanate, or bromide ions, eosinophil peroxidase provides a potent mechanism by which eosinophils kill multicellular parasites (such as the nematode worms involved in filariasis) and some bacteria (such as tuberculosis bacteria). Eosinophil peroxidase is a haloperoxidase that preferentially uses bromide over chloride for this purpose, generating hypobromite (hypobromous acid), although the use of chloride is possible.
== Complications == The denaturing of proteins by an aqueous solution containing many types of ions is more complicated as all the ions can act, according to their Hofmeister activity, i.e., a fractional number specifying the position of the ion in the series (given previously) in terms of its relative efficiency in denaturing a reference protein. At high salt concentrations lysozyme protein aggregation obeys the Hofmeister series originally observed by Hofmeister in the 1870s, but at low salt concentrations electrostatic interactions rather than ion dispersion forces affect protein stability resulting in the series being reversed. However, at high concentrations of salt, the solubility of the proteins drops sharply and proteins can precipitate out. Ion binding to carboxylic surface groups of macromolecules can either follow the Hofmeister series or the reversed Hofmeister series depending on the pH. The concept of Hofmeister ionicity Ih has been invoked by Dharma-wardana et al. where it is proposed to define Ih as a sum over all ionic species, of the product of the ionic concentration (mole fraction) and a fractional number specifying the "Hofmeister strength" of the ion in denaturing a given reference protein. The concept of ionicity (as a measure of the Hofmeister strength) used here has to be distinguished from ionic strength as used in electrochemistry, and also from its use in the theory of solid semiconductors.
mTOR is the catalytic subunit of two structurally distinct complexes: mTORC1 and mTORC2. The two complexes localize to different subcellular compartments, thus affecting their activation and function. Upon activation by RHEB, mTORC1 localizes to the Ragulator-Rag complex on the lysosome surface where it then becomes active in the presence of sufficient amino acids.
=== Microchimerism === Microchimerism of fetal cells (offspring lymphoid cells in maternal circulation) may generate autoimmunity in women who have previously been pregnant. Generation of an autoimmune potential via microchimerism may lead to a switch from a silent form of autoimmunity with age-dependent decrease in self-tolerance.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.